Truist Securities analyst Srikripa Devarakonda raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $709.00 (from $640.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE